# A Study of rSIFN-co in Subjects With Advanced Solid Tumors

> **NCT02387307** · PHASE1 · COMPLETED · sponsor: **Sichuan Huiyang Life Science and Technology Corporation** · enrollment: 42 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Melanoma
- Carcinoma, Hepatocellular
- Colon Cancer

## Interventions

- **DRUG:** rSIFN-co

## Key facts

- **NCT ID:** NCT02387307
- **Lead sponsor:** Sichuan Huiyang Life Science and Technology Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02387307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02387307, "A Study of rSIFN-co in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02387307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*